Cardiovascular Effects of Neuregulin-1/ErbB Signaling: Role in Vascular Signaling and Angiogenesis

Author(s): Nadia Hedhli, April Kalinowski, Kerry S. Russell

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 30 , 2014

Become EABM
Become Reviewer
Call for Editor


The NRG/erbB pathway has emerged as an important therapeutic target for cancer growth as well as cardiac related diseases. This discovery stems back to findings showing that overexpression of erbB2 receptors increases the metastatic potential of breast cancer in patients. Blocking this receptor using a monoclonal antibody (trastuzumab) inhibits tumor growth and offers significantly improved outcomes. However, excitement over this discovery was tempered by data showing that trastuzumab-treated patients have an increased risk of developing cardiac dysfunction, limiting the clinical potential of this novel agent. This finding suggested an important protective effect of the erbB signaling pathway on cardiac survival and homeostasis. Further investigation has shown that endothelial-derived neuregulin (a key ligand for erbB receptors) has a protective paracrine effect on cardiac cells as well as vascular smooth muscle cells in the setting of an injury. Since endothelial cells contain erbB receptors, they are also targets for autocrine signaling via this pathway, an important mediator of vascular preservation and angiogenic responses of endothelium. In this review we summarize important clinical findings as well as animal and cellular models that illustrate the signaling pathways involved in vascular cell regulation of cardiomyocyte survival and angiogenesis via the NRG/erbB pathway.

Keywords: erbB, neuregulin, endothelial cells, trastuzumab, cancer, heart failure, smooth muscle cells, angiogenesis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 10 August, 2014
Page: [4899 - 4905]
Pages: 7
DOI: 10.2174/1381612819666131125151058
Price: $65

Article Metrics

PDF: 69